Martin M F, Surrall K E, McKenna F, Dixon J S, Bird H A, Wright V
Lancet. 1984 Jun 16;1(8390):1325-8. doi: 10.1016/s0140-6736(84)91821-x.
Captopril, an inhibitor of angiotensin converting enzyme, is prescribed for hypertension. Its molecular structure shares features with D-penicillamine, in that both agents contain a thiol group. In addition, captopril has immunosuppressant activity. Captopril was therefore considered a potential slow-acting drug for treating rheumatoid arthritis. In an open study 15 patients with active arthritis were treated with captopril and followed for 48 weeks. Two-thirds of the patients reported improved arthritis symptoms, and significant changes were seen in several clinical and biochemical measurements, notably Ritchie articular index, clinical score, plasma viscosity, and C-reactive protein. Side-effects were generally mild and included transient taste loss, rashes, and hypotension. Only 2 patients withdrew as a result of drug intolerance.
卡托普利是一种血管紧张素转换酶抑制剂，用于治疗高血压。它的分子结构与D-青霉胺有共同特点，即两种药物都含有一个巯基。此外，卡托普利具有免疫抑制活性。因此，卡托普利被认为是一种治疗类风湿性关节炎的潜在慢效药物。在一项开放性研究中，15例活动性关节炎患者接受了卡托普利治疗，并随访48周。三分之二的患者报告关节炎症状有所改善，在几项临床和生化指标上出现了显著变化，尤其是里奇关节指数、临床评分、血浆粘度和C反应蛋白。副作用一般较轻，包括短暂的味觉丧失、皮疹和低血压。只有2例患者因药物不耐受而退出研究。
